Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Marc Van den Eynde et al.|The Lancet Oncology|2024Cited by 124
A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor ReceptorAislyn Boran, Ravi Iyengar|PLoS ONE|2012Cited by 28
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Merrick I. Ross et al.|Journal of Clinical Oncology|2016Cited by 19